Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection aims to tackle hidden heart risk

NCT ID NCT07640217

Disease control Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an experimental injection called SYH2068 in 120 adults with high lipoprotein(a), a genetic risk factor for heart disease. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels over several months. The goal is to find a new way to manage this stubborn risk factor.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SYH2068 injection
What this could lead to
If successful, this could lead to a new treatment option to lower high lipoprotein(a) levels, potentially reducing heart disease risk.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not confirm effectiveness or safety. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female participants ≥18 years of age; 2. Elevated Lp(a); 3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs; 4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk; 5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF. Exclusion Criteria: 1. Diseases that significantly affect Lp(a) during screening period, 2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization; 3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period; 4. NYHA class III-IV at the time of signing the ICF or LVEF \<40% during the screening period; 5. Type 1 diabetes or hereditary hemorrhagic disorder at screening; 6. History of malignant tumor or suspected malignancy within 5 years prior to screening; 7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period; 8. Allergy to oligonucleotide drugs; 9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug; 10. Female participants who are pregnant or breastfeeding at screening, or female / male participants who plan to conceive during the study and within 1 year after the last dose.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult participants with elevated lipoprotein(A) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult participants with elevated lipoprotein(A)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.